Nanology Labs is developing a novel thernaostic agent (contrast agent for MRI) that enables early detection of tumors using MRI. At the same time, it sensitizes cancer cells, improving the outcome of radiation therapy and leading to a five-fold increase in patient life expectancy and a 40% cure rate after radiation.

Why we invested ?

Nanology Labs won the MEDTEQ+ pitch competition. Out of 55 applicants and 5 final pitches, Nanology was selected as the winner. The judges were impressed with the significant reduction in academic risk that has been put in place so far, combined with significant non-dilutive funding.